U.S. Markets open in 4 hrs 29 mins

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
186.29+0.53 (+0.29%)
At close: 4:15PM EDT
People also watch
BIIBGILDCELGMRKBMY
  • m
    mtwashingtonmike
    mtwashingtonmike
    Five down days in a row? This is starting to look like the breakout that wasn't.
  • A
    Ashley
    Ashley
    I think AMGN might have reached its upward limit and that a pullback may be possible. I started receiving notifications from Awe-Some.Sto-ck.s the other week and so far they have presented interesting new trade ideas.
  • E
    Emily
    Emily
    The scenarios are quite interesting at current levels for AMGN. Ive been struggling with this stock lately. Some of my other trades have been from awesom_sto-cks which are working out pretty well.
  • T
    Tad
    Tad
    $ARWR conversation

    from sa advisory

    On Sept 14, 2017 key personal will discuss the advancements of ARWR and also the joint venture with AMGN. To recap~ ARWR will provide an overview of the Company's new platform technology and its pipeline of RNAi- based therapeutics. This discussion will include:

    1. The targeted RNAi Molecule (TRiM) Platform, which includes targeted to the liver, tumors, and another tissue to be disclosed at the event.

    2.ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency,

    3. ARO-HBV for chronic hepatitis B infection

    4. ARO-APOC3 for cardiovascular diseases

    5. Updates on ARWR's clinical development timelines

    Note: A live and achived webcast of the event,with slides~ http://ir.arrowheadpharma.com/events.cfm.

    Please recall back on Sept 29th 2016 ARWR/AMGN created a Cardiovascular Collaboration for 2 RNAi therapeutics. The Total deal value of up to $673.5 million. ARWR received $56 million up front. The herd will have "big ears" concerning the outcome of this collaboration. Via the grapevine there has been chatter that both companies will be formally introducing a FDA filing on potential drug testing . If the mere mention of this advanced FDA process they herd will have a bullish stampede on the upside and shorts will hang themselves if they can even afford the rope!

    Biotechs are the toughest investment speculation to be found anywhere. If cash burn-rate was not hard enough to swallow you then need to deal with "gods" of the FDA! Fortunes can be had as well as potentially vying for an abandoned shopping cart.

    Like a "hurricane" the FDA can clip millions or billions off the value of a company's market-cap with a 4 letter word-"DENY"!

    Last November 2016 the FDA "clipped" ARWR when the Arrow's lab somehow OD'd a few chimps and regardless how successful the human trial had gone- the FDA punished ARWR causing the stock to free fall from $6.00 to $1.20! Faster than a hand of Blackjack !

    At the same time AMGN decided to throw ARWR a small bone with the possibility of a large Dinosaur bone ($622,000,000.00) if results from a new platform could create a Cardio cancer drug. At present AMGN is funding the company for their research with more money to be released if results are juicy enough!

    We still believe that ARWR is still deep into their RNAi based therapeutic platform. In a nutshell RNAi is the mechanism that offers a pathway of gene silencing to target and shut down specific genes that cause disease.

    Note: go to www.amgenscience.com and click,"the shape of drugs and go down and click RNAi. There is more than meet the eye between AMGN/ARWR.

    The large sum of money mentioned above with AMGN deals with a program to utilize ARWR's proprietary subcutanous RNAi delivery platform for therapies for cardiovascular disease. Part of the agreement grants AMGN worldwide, exclusive license to ARWR's novel, RNAi-ARC-LPA program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease.

    In our opinion, if AMGN continues to like the results i see very little reason why AMGN would continue to fund the company, but instead just buy them.

    ARWR is extremely rich with patents, technology and capable science so AMGN gets many valuable extras. Lately, the Biotech segment has been active in the M&A area -KITE was just swallowed by Gilead for $12 billion! Many of these Biotech's are swimming with hordes of cash and i believe Gilead has just woken up the major players to start grabbing deals before the other guy snags them!

    AMGN is a "GOD" of the Biotech sector. At present they have $39,000,000,000 in cash and their stock is $180.00/sh and there are around 730 million shares outstanding.

    The fantasy: Amgen buys ARWR for $20/sh because the results announced on Sept 14th and beyond indicate enormous potential. If AMGN paid cash that would only be $1.5 Billion. Personally, if i was AMGN i would use their stock and it would only cost around 8.3 million shares of AMGN stock. Like a drop of water in a puddle.

    Food for thought: Silence Therapeutics owns over 9% of ARWR free trading shares.

    phone: +44 (0)20 3457 6900

    website: www.silence-therapeutics.com

    The company is heavy into RNAi research and development.

    We have been involved in ARWR for a number of years and have felt the euphoria and level 9 of HELL!

    ARWR has been involved with Gilead (GILD-$85) ,Novartis (NVS-$86) and Amgen (AMGN-$180).

    It is only a matter of time before one of these giants takes out ARWR because of their results, platforms, science, patents and most importantly results. We rate ARWR with a strong buy rating. It maybe like playing dice, but in our case even if you throw a snake eyes we still have the potential to throw 7 at a later date.

    On Sept 14, 2017 the cards will be on the table. There will be 3 options: 1.the street already assumed the steady potential with AMGN and the stalls and the short lick their chops!

    2. Results are less than anticipated and the stocks drops to low $2 range even though AMGN continues the research and still will fund.

    3. We hit certain milestones and results are very favorable and the stock rockets!

    Regardless, we believe a good price ($3.39) to build a position in this biotech opportunity with amazing upside potential .

    $ARWR $GILD $AMGN $NVS

  • m
    mtwashingtonmike
    mtwashingtonmike
    Amgen in a funk today? Anybody have any insight.
  • E
    Emily
    Emily

    Who says AMGN isn't poised for potentially massive upward movement? check out https://activepennystocks1.blogspot.com, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.

  • b
    brian
    brian
    What going with AMGN? Is there some bad news?
  • S
    Steve
    Steve
    Aren't you glad you own AMGN? Paid about 46 in 1990's. Glad I did.
  • A
    Anonymous
    Anonymous
    split this stock and watch it run up! 3 for 1.
  • M
    Marc
    Marc
    $GILD conversation

    Wall Street Best Biotech Investment Advisor Portfolio Soars to All-Time Highs $KITE $GILD $AMGN $BIIB $BLUE $ISRG $ILMN $VRTX https://www.youtube.com/watch?v=3EDC8ZojUik

    Wall Street Best Biotech Investment Advisor Portfolio Soars to All-Time Highs
    https://stockmarketLIVE.TV stock market Live News. Live streaming trading. Live stock forecasts. Trading Courses. Live Earnings Calls. Markets Live Analysis....
    www.youtube.com
  • G
    GaryC
    GaryC
    Look for heavy profit taking after yesterdays gains.
  • Y
    Y
    Y
    Trump got a loose FDA
  • A
    Anonymous
    Anonymous
    According to Nasdaq, analysts have the following estimates for ENDP:

    (18)$3.09 (19)$3.45 (20)$3.94

    If ENDP just trades at 6x forward estimates, ENDP is a $22-24 stock. Finally, it's also important to note that ENDP's management recently guided 20 new drug launches for 2017 and over 20 new regulatory drug filings for this fiscal year. Good luck to all 🐻
  • B
    BioLover
    BioLover

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • G
    Grace
    Grace

    http://jcharlesassets.com/opiant-pharmaceuticals/?s=AMGN has an alert for $AMGN. Did anyone happen to see it as well? Looking for some good positive information from the company! "rht" Trading stocks making money.

    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • C
    Crecy
    Crecy
    Why is AMGN going down?
  • D
    Derek
    Derek

    VODG is picking up steam on its Brain Regeneration therapy. Their latest clinical trial that they have been conducting for the past 3.5 years has just yielded positive results for Autism. This is on top of the fact they are already in clinical trials for Brain Regenerative therapy for Concussions. https://finance.yahoo.com/news/vitro-biopharma-reports-positive-clinical-133000325.html

    Vitro Biopharma Reports Positive Clinical Trial Results of Stem Cell Activation Therapy for Autism
    GOLDEN, CO / ACCESSWIRE / August 8, 2017 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma, announced initial results of a Phase I clinical trial testing the effects of its proprietary stem ...
    finance.yahoo.com
  • s
    shep
    shep
    The report looked good to me. I don't see any reason for it being down in after hours.
  • M
    Mo
    Mo
    Down after earnings, but I see a potential break-out and new highs
  • w
    whooz yor daddy
    whooz yor daddy
    Buy the dip: ....operating margin improved by 4.9 percentage points to 48.4%. AMGN also raises its FY17 adjusted EPS outlook to $12.15-$ 12.65 from $12-$12.60 and narrowed its revenue guidance to a range of $22.5B to $23B. The company reports adjusted EPS of $3.27 on $5.81B in sales,